



OPEN

Decisions and disease: a mechanism for the evolution of cooperation

Carl-Joar Karlsson^{1,2} & Julie Rowlett^{1,2}✉

In numerous contexts, individuals may decide whether they take actions to mitigate the spread of disease, or not. Mitigating the spread of disease requires an individual to change their routine behaviours to benefit others, resulting in a 'disease dilemma' similar to the seminal prisoner's dilemma. In the classical prisoner's dilemma, evolutionary game dynamics predict that all individuals evolve to 'defect.' We have discovered that when the rate of cooperation within a population is directly linked to the rate of spread of the disease, cooperation evolves under certain conditions. For diseases which do not confer immunity to recovered individuals, if the time scale at which individuals receive accurate information regarding the disease is sufficiently rapid compared to the time scale at which the disease spreads, then cooperation emerges. Moreover, in the limit as mitigation measures become increasingly effective, the disease can be controlled; the number of infections tends to zero. It has been suggested that disease spreading models may also describe social and group dynamics, indicating that this mechanism for the evolution of cooperation may also apply in those contexts.

Decisions made by individuals affect the population, not the least in disease spreading. Several researchers have investigated the interplay between diseases and decisions by combining compartmental models with game theory¹⁻⁵. Common considerations are dynamics on networks or lattices⁵⁻¹⁸ and well-mixed populations¹⁹⁻²⁸. The former's strength is that it captures the effect of population structures, while the latter's strength is that it highlights the individuals' perception of the payoff. We consider a society in which individuals choose to what extent they will exert preventive measures to mitigate the spread of an infectious disease. The population may range from having a social network structure to being well-mixed. Individuals have two choices: exert mitigating measures to prevent the spread of the disease, and do-not-mitigate, making no efforts to prevent the spread of the disease. Individuals do not necessarily maintain the same choice; they are free to change their behaviors based on their perception of cost versus benefit. The World Health Organisation²⁹ and numerous other references including³⁰⁻³² argue that it is reasonable to describe this situation with the Prisoner's Dilemma (PD).

The payoffs may be interpreted as in Fig. 1. If both Alice and Bob defect, then they pay no cost but also receive no benefit, hence their payoffs are both $P = 0$. Let us consider the particular example of cloth face masks. If Alice cooperates while Bob defects, then Alice pays the cost of buying the mask and enduring its discomforts, which is represented by $-B < 0$. As demonstrated in³³ Alice receives a small amount of protection from her mask, represented by $\epsilon > 0$, but the main benefit is reaped by everyone else. Consequently, if Bob does not wear a mask, he pays no cost but receives a benefit of $T > \epsilon > 0$. Alice's total payoff is therefore $-B + \epsilon$. Since the benefit to Alice is relatively small, we assume further that $\epsilon < B$. If both Alice and Bob cooperate, then they both pay the cost $-B$, but they also receive the maximal protective benefit of $T + \epsilon$, and their total payoffs are thus $T - B + \epsilon$. Consequently, defining

$$C := B - \epsilon,$$

the payoffs satisfy

$$S = -C < P = 0 < R < T = R + C. \quad (1)$$

This particular representation of the Prisoner's Dilemma is known as the Donor-Recipient game. The two-player game generalizes to a population-level model³⁴ in which all individuals in the population choose whether or

¹Department of Mathematical Sciences, Chalmers University of Technology and The University of Gothenburg, 41296 Gothenburg, Sweden. ²These authors contributed equally: Carl-Joar Karlsson and Julie Rowlett. ✉email: julie.rowlett@chalmers.se






What should I do? 	Cooperate – wash hands, wear face mask. 	Defect – no change to behavior. 
Payoffs when I choose to cooperate. 	(R, R)	(S, T)
Payoff when I choose to defect. 	(T, S)	(P, P)

Figure 1. In the ‘disease dilemma’ people have the choice to cooperate, mitigating the spread of the disease, or defect, making no change to their regular behaviour. This is described by the non-cooperative game shown here in normal form. Image source and license: openclipart.org, CC01.0.

not to mitigate the spread of disease. In a well-mixed population, everyone interacts with each other, which is described by a fully connected graph. In reality, however, it is possible that certain individuals never interact, which can be described using a social network^{34–37}. The presence of such a network modifies the payoffs (1), in such a way that if the social pressure is just right, cooperation may become more beneficial than defecting, an effect known as network reciprocity.

The payoffs (1) are modified by a quantity $N(k)$, where k is the average node degree in the network, corresponding to the average number of social contacts each individual has. Making a standard set of simplifying assumptions as in^{34–38} allows us to incorporate the societal network structure and nonetheless obtain tractable expressions which are amenable to explicit analyses; see SI § “Network Reciprocity” for further details. The payoffs R and P remain as in (1), whereas the network structure now modifies the payoffs S and T

$$S = -C + N(k), \quad T = R + C - N(k), \quad N(k) := \frac{Rk - 2C}{(k + 1)(k - 2)}, \quad k \in \mathbb{N} \setminus \{2\}, \quad N(2) := R. \quad (2)$$

The quantity $N(k)$ increases with R , and tends to zero when $k \rightarrow \infty$. For intermediate values of k , this may be interpreted as social pressure, for example in a group of twenty persons all wearing masks, there is pressure to conform and also wear a mask. Consequently, $N(k)$ increases the payoff value of S and decreases the payoff value of T . When $k \rightarrow \infty$, $N(k) \rightarrow 0$, and the model describes a well-mixed society. Although the model is still essentially based on pairwise interactions, dyadic games nonetheless are widely applicable to understanding societal level issues including but not limited to political crises³⁹, vaccine compliance⁴⁰, antibiotic resistance⁴¹, and cultural diversity⁴². Moreover, some argue that simple, transparent models from which insights are readily apparent may be of greater use than more complicated models⁴³.

In the society-wide disease dilemma considered here, the unique equilibrium strategy is total defection. When this game is used to predict behaviours according to evolutionary game dynamics, the result is always defection⁴⁴. Nonetheless, in many contexts which fit into a PD type game, cooperation may in fact be observed^{45–51}. In the particular case of the PD, there have been numerous mechanisms proposed for the evolution of cooperation^{38,52}. To our knowledge, it has been unknown—until now—whether cooperation emerges when the payoff is a trade-off between the PD and the effect on disease spreading through changes to the infection transmission rate.

Methods

Infections like those from the common cold, flu, and many sexually transmitted diseases do not confer any long-lasting immunity, and individuals become susceptible once they recover from infection. These diseases are therefore described by the SIS compartmental model. Poletti et al.⁵³ implemented a hybrid model in which human decisions affect the rate at which the disease spreads. They assigned two different rates of infection corresponding to individuals either changing their behaviour to mitigate the spread of the disease, or not doing so. We follow this approach by assigning the rates of infection for cooperators and defectors, $\beta_C < \beta_D$, respectively. In a population comprised entirely of cooperators, susceptible individuals become infected at the rate $\beta_C I(t)$. In a population comprised entirely of defectors, susceptible individuals become infected at the rate $\beta_D I(t)$. In both cases, $I(t)$ represents the pool of infectious individuals. In a mixed population, where the proportion of cooperators is $x = x(t)$, and defectors is $1 - x = 1 - x(t)$, susceptible individuals become infected at the rate $\beta(t)I(t)$, where

$$\beta(t) = (1 - x(t))\beta_D + x(t)\beta_C. \quad (3)$$

Since the portion of cooperators and defectors changes over time, the rate of infection, $\beta = \beta(t)$, is also a dynamical parameter, changing over time. The SIS-PD replicator equations with these considerations read

$$\begin{aligned} \frac{dI}{dt} &= [(1 - x(t))\beta_D + x(t)\beta_C]I(t)(1 - I(t)) - \gamma I(t), \\ \frac{dx}{dt} &= x(t)(1 - x(t))[(\beta_D - \beta_C)I(t) - ([T - R]x(t) + [P - S](1 - x(t)))]. \end{aligned}$$

Above, the quantities on the left side are differentiated with respect to $t = \text{time}$. The rate at which infected individuals become susceptible again is γ . If D is the average duration of the infection, then $\gamma = 1/D$. We note that $1 - I(t)$ is the portion of the population which is susceptible to infection, since in this model there is no immunity.

We would like to allow susceptible individuals to change their behavior spontaneously, corresponding to cost and benefit considerations. Choosing to mitigate, corresponding to the transmission rate β_C incurs a cost, but reduces the risk of infection. Choosing not to mitigate increases the transmission rate of the population but does not incur any cost. The choice individuals make depends on the current state of the epidemic. It is important to note that the choice of behavior need not occur at the same time scale as the epidemic. The decision whether or not to take mitigation measures is based on the information to which one has access, via email, phone, internet, and media. On the other hand, epidemic transmission can occur only through interpersonal contact.

To implement the fact that decision-making and disease-spreading do not necessarily occur at the same time scales, we introduce the parameter $\alpha_1 \in \mathbb{R}$, which may be positive, negative, or zero. Large values of $|\alpha_1|$ correspond to frequent exposure to information regarding the disease. When $\alpha_1 > 0$, this corresponds to accurate information recommending disease avoidance, whereas when $\alpha_1 < 0$, this corresponds to (mis)-information which may suggest either the disease is harmless or that it is beneficial to contract the disease. The value $\alpha_1 = 0$ corresponds to no information regarding the disease, or equivalently, ignoring the disease’s existence. Consequently, the timescale of disease transmission is t , while the timescale at which individuals receive disease-related information is $|\alpha_1|^{-1}t$. There is also no reason that the timescale of disease transmission is equal to the timescale at which individuals either pay the cost of cooperating or reap the benefits of defecting in the presence of cooperators. To reflect this generality, we introduce the parameter $\alpha_2 > 0$, so that the timescale at which individuals receive PD payoffs is $\alpha_2^{-1}t$.

The decision whether to cooperate or defect is influenced by an individual’s social contacts, as described by a social network structure^{34–37}. Recalling the PD payoffs which incorporate this network structure, (2), and with all of the above considerations in mind, the replicator equations for our hybrid SIS-PD model now read

$$\frac{dI}{dt} = ([1 - x(t)]\beta_D + x(t)\beta_C)I(t)(1 - I(t)) - \gamma I(t), \tag{4}$$

$$\frac{dx}{dt} = x(t)(1 - x(t))[\alpha_1(\beta_D - \beta_C)I(t) - \alpha_2(C - N(k))]. \tag{5}$$

Since $\beta_D > \beta_C$, if $\alpha_1 > 0$, and $C - N(k) > 0$, the terms in the equation for the evolution of cooperators have opposite signs, resulting in a competition between avoidance of disease carriers and PD reward. We note that as soon as $C - N(k) \leq 0$, the game ceases to be of PD-type. For further details concerning the derivation of these equations, see SI “Transmission rates for cooperators and defectors”.

Similar calculations lead to the replicator equations for the SIR-PD model

$$\begin{aligned} \dot{\mathcal{S}}(t) &= -((1 - x(t))\beta_D + x(t)\beta_C)\mathcal{S}(t)I(t) \\ \dot{I}(t) &= ((1 - x(t))\beta_D + x(t)\beta_C)\mathcal{S}(t)I(t) - \gamma I(t) \\ \dot{\mathcal{R}}(t) &= \gamma I(t) \\ \dot{x}(t) &= x(t)(1 - x(t))(\alpha_1(\beta_D - \beta_C)I(t) - \alpha_2(C - N(k))) \end{aligned} \tag{6}$$

Above, \mathcal{S} is the number of susceptible individuals, and the quantities on the left are all differentiated with respect to time. If the portion $\gamma I(t)$ of infectious individuals recovers and acquires long-lasting immunity, we may describe the accumulated number of these individuals with a third compartment, namely \mathcal{R} , which is generally the number of recovered and immune, and/or deceased, individuals. The parameter γ is the rate at which infected individuals either recover or die. If D is the average duration of the infection, irrespective of the outcome (recovery or death), then $\gamma = 1/D$, as in the SIS-PD model. This model is reasonably predictive for infectious diseases that are transmitted from human to human, and where recovery confers lasting resistance. Since $\mathcal{S} + I + \mathcal{R} = 0$, the triplet (x, I, \mathcal{S}) describes the complete system; for further details see SI § “Transmission rates for cooperators and defectors”.

Results

The network structure may cause the game to cease to be of PD type. For $k = 1$, the game is always of PD type. For $k \geq 2$, the game is no longer of PD type if $C - N(k) \leq 0$, which is equivalent to

$$\frac{R}{C} \geq k - 1. \tag{7}$$

If $\frac{R}{C}$ is large, corresponding to low costs of mitigation and/or high benefit of mutual cooperation, the game may cease to be of PD type for sufficiently small values of k such that the above inequality holds. However, since the right side of (7) tends to infinity when $k \rightarrow \infty$, for sufficiently large values of k , the game is always of PD type. On the other hand, when $\frac{R}{C}$ is small, corresponding to either minimal benefit of mutual cooperation or extreme

Range	Equilibrium
$\alpha_1 < \check{\alpha}_1$	$(0, 1 - \gamma/\beta_D)$
$\check{\alpha}_1 \leq \alpha_1 \leq \hat{\alpha}_1$	(x^*, I^*)
$\hat{\alpha}_1 < \alpha_1$	$(1, 1 - \gamma/\beta_C)$

Table 1. The asymptotically stable equilibrium points of the SIS-PD model in the specified ranges of α_1 , where $\check{\alpha}_1$ and $\hat{\alpha}_1$ are defined in (8).

costs of mitigation, then there may be no value of k such that (7) holds, and so the game is always of PD type. Since our focus is the emergence of cooperation for a PD type game, we henceforth assume that the game is of PD type, and therefore we assume that $C - N(k) > 0$. We shall also assume that $\alpha_1 > 0$, because if $\alpha_1 \leq 0$, all individuals simply evolve to defect.

SIR-PD equilibrium points. For the SIR-PD model, the complete set of equilibrium points consists of (x, I, \mathcal{S}^*) with

$$x \in \{0, 1\}, \quad I = 0, \quad 0 \leq \mathcal{S}^* \leq 1.$$

The equilibrium points with $x = 0$ are stable if $\beta_D \mathcal{S}^* \leq \gamma$. When the reverse inequality holds, the equilibrium point is unstable. All equilibrium points with $x = 1$ are unstable. For the details of these calculations, see SI “Calculation and classification of all equilibrium points in the SIR-PD model”.

SIS-PD equilibrium points. The equilibrium points of the SIS-PD system are the set of (x, I) :

$$\left\{ (0, 0), (1, 0), \left(0, 1 - \frac{\gamma}{\beta_D}\right), \left(1, 1 - \frac{\gamma}{\beta_C}\right), (x^*, I^*) \right\}, \quad x^* = \frac{\beta_D}{\beta_D - \beta_C} - \frac{\gamma}{(\beta_D - \beta_C)(1 - I^*)}, \quad I^* = \frac{\alpha_2(C - N(k))}{\alpha_1(\beta_D - \beta_C)}.$$

The equilibrium point, (x^*, I^*) , is well-defined as long as $x^* \in [0, 1]$, and $I^* \in [0, 1]$, since $C - N(k) > 0$, and $\alpha_1, \alpha_2 > 0$. We compute that

$$I^* < 1 \iff \frac{\alpha_2(C - N(k))}{\beta_D - \beta_C} < \alpha_1.$$

We further compute

$$0 \leq x^* \leq 1 \iff \check{\alpha}_1 \leq \alpha_1 \leq \hat{\alpha}_1, \quad \check{\alpha}_1 = \frac{\beta_D}{\beta_D - \gamma} \frac{\alpha_2(C - N(k))}{\beta_D - \beta_C} \quad \text{and} \quad \hat{\alpha}_1 = \frac{\beta_C}{\beta_C - \gamma} \frac{\alpha_2(C - N(k))}{\beta_D - \beta_C}. \tag{8}$$

Since $1 < \beta_D/(\beta_D - \gamma)$, this condition immediately implies $I^* < 1$. We note that

$$\frac{\beta_D}{\beta_D - \gamma} < \frac{\beta_C}{\beta_C - \gamma} \implies \frac{\beta_D}{\beta_D - \gamma} \frac{\alpha_2(C - N(k))}{\beta_D - \beta_C} < \frac{\beta_C}{\beta_C - \gamma} \frac{\alpha_2(C - N(k))}{\beta_D - \beta_C}.$$

Whenever it exists, the equilibrium point (x^*, I^*) is *always* stable (and asymptotically stable).

The equilibrium point $(0, 0)$ is stable (and asymptotically stable) if

$$\beta_D < \gamma, \quad C - N(k) > 0.$$

Since $x\beta_C + (1 - x)\beta_D \leq \beta_D$,

$$\frac{dI}{dt} = [(x\beta_C + (1 - x)\beta_D)(1 - I) - \gamma]I \leq 0,$$

with equality only if $I = 0$, and hence there is no epidemic. The equilibrium point $(1, 0)$ is never stable for PD payoffs. The equilibrium point $(0, 1 - \gamma/\beta_D)$, is well defined if $\beta_D \geq \gamma$, because $0 \leq I \leq 1$, and it is stable (and asymptotically stable) if

$$\alpha_1(\beta_D - \beta_C)(1 - \gamma/\beta_D) < \alpha_2(C - N(k)).$$

For PD payoffs (2), this is equivalent to

$$\alpha_1 < \check{\alpha}_1 \tag{9}$$

The equilibrium point $(1, 1 - \gamma/\beta_C)$ is well defined if $\beta_C \geq \gamma$. It is stable (and asymptotically stable) if

$$\alpha_2(C - N(k)) < \alpha_1(\beta_D - \beta_C)(1 - \gamma/\beta_C).$$

For PD payoffs (2), this equilibrium point is stable (and asymptotically stable) when

$$\hat{\alpha}_1 < \alpha_1. \tag{10}$$




Figure 2. The values of β_D and γ above were suggested⁵⁴; however these values can be modified to any disease parameters. Since it is the relationship between α_1 and α_2 , rather than their individual values which affects the dynamics, we simply fix $\alpha_2 = 0.1$. The value of α_1 ranges along the horizontal axis. The vertical axis is used to indicate both the frequency of cooperators, x , as well as the frequency of infectious individuals, I , within the population. For sufficiently large α_1 , the population evolves to cooperation. At the same time, the more effective the mitigation measures are, the lower β_C is, which pushes the portion of infectious individuals to zero. More precisely, when $\alpha_1 \geq \hat{\alpha}_1$, then $\lim_{\beta_C \searrow \gamma} I = 0$.




Figure 3. The evolution to cooperation depends on the relationship between α_1 and α_2 , when the parameters β_D and γ are as suggested in⁵⁴ and with $C - N(k) = 2$ (left figure) or $C - N(k) = 0.75$ (right figure). Here the value of β_C corresponds to moderately effective mitigation measures. As $C - N(k)$ decreases, cooperating dominates a larger domain.

Our results are summarised in Table 1. Figure 2 shows how the evolution of cooperation and the rate of infections depend on α_1 and β_C when $\beta_D = 1.68$ and $\gamma = 1/5$ as suggested in⁵⁴. We note that these values were selected merely for the sake of visualisation, as our theoretical results hold for any parameter values. If both α_1 and α_2 vary, we obtain convergence to cooperation as shown in Fig. 3. Figure 4 shows that the numerical integration agrees perfectly with the analytical results. Note that the dependence on *both* α_1 and α_2 is actually a dependence on their *ratio*, since all the stability limits can be written as inequalities for the unknown α_1/α_2 .




Figure 4. The results from numerical integration agree with the analytical results. The values of β_D and γ above were suggested⁵⁴. The vertical axis is used to indicate both the frequency of cooperators, x , as well as the frequency of infectious individuals, I , within the population. Here the value of β_C corresponds to mitigation measures which are more effective than in Fig. 3 but still imperfect.

Discussion

It has been suggested that mass media could be used to reduce HIV-infections⁵⁵, and that this approach may explain the success in controlling HIV in Australia^{56,57}. If an infectious disease, like HIV, does not confer immunity to those who recover from it, then SIS is a suitable model. The rate of spread for those who make no mitigation efforts, β_D , is strictly larger than the rate of spread for those who make mitigation efforts, β_C . Our results show that the relationship between the timescale of decision making and the timescale of PD payoffs is crucial. Decision-making is influenced by the speed at which individuals access or receive information upon which to base their decisions. It is reasonable to assume that the timescale of PD payoffs is similar to the timescale t for the spread of disease, or at least on the same order of magnitude. On the other hand, the speed at which individuals can access information could be much faster. This corresponds to $\alpha_1 \gg \alpha_2$. When $\alpha_1 > \hat{\alpha}_1$, the equilibrium point $(1, 1 - \gamma/\beta_C)$ exists. Consequently, for sufficiently large α_1 , the *unique* equilibrium point of the system corresponds to total cooperation. Moreover, in this case the portion of the population which is infected tends to $1 - \gamma/\beta_C$. We therefore also have

$$\lim_{\beta_C \searrow \gamma} 1 - \frac{\gamma}{\beta_C} = 0. \tag{11}$$

This shows that in the limit towards effective mitigation measures, the rate of the population which is infected tends to zero. We summarise these insights below.

In the context of a communicable disease which does not confer immunity, if accurate information is made available to all individuals quickly relative to the spread of the disease, all rational individuals acting in their best self interest will evolve to cooperate by taking measures to mitigate the spread. Simultaneously, increasingly effective mitigation measures drive the rate of infectious individuals to zero.

These insights suggest a strategy for controlling diseases which do not confer immunity and may apply to SARS-CoV-2, as recent studies indicate that the disease might not confer immunity^{58–60}. More generally, this strategy may be applied in the context of new diseases, for which it is unknown and unknowable whether contracting and recovering from the disease grants immunity⁶¹. Vaccines require time for development and testing⁶². It may therefore be prudent to use the SIS model for new communicable diseases. The value of α_1 may be associated to the frequency of public service announcements (PSAs) which accurately convey effective mitigation measures. The more frequent the PSAs, the higher the value of α_1 . Our results prove that when α_1 becomes sufficiently large, cooperation emerges, and the amount of infections can be controlled. Moreover, when mitigation measures are made increasingly effective, in the limit the frequency of infectious individuals tends to zero. The perceived benefit of defecting is defined by the PD payoffs (2), so that defecting is still perceived to offer benefits if others cooperate. The key to the evolution for cooperation is the time scale for decision making. This can be much faster than the time scale at which one can actually reap the benefits of defecting. When this is the case, the population evolves towards cooperation. Our results are not constrained to any specific disease, but rather suggest a general strategy to promote the evolution of cooperation in the Donor–Recipient game when linked to the SIS model. The

SIS model has further applications to describing social and group dynamics²⁵. Our model may thereby provide a mechanism for the evolution of cooperation in social contexts as well.

Received: 15 May 2020; Accepted: 13 July 2020

Published online: 04 August 2020

References

1. Funk, S., Salathé, M. & Jansen, V. A. A. Modelling the influence of human behaviour on the spread of infectious diseases: a review. *J. R. Soc. Interface* **7**, 1247–1256. <https://doi.org/10.1098/rsif.2010.0142> (2010).
2. Verelst, F., Willem, L. & Beutels, P. Behavioural change models for infectious disease transmission: a systematic review (2010–2015). *J. R. Soc. Interface* **13**, 20160820 (2016).
3. Weston, D., Hauck, K. & Amlôt, R. Infection prevention behaviour and infectious disease modelling: a review of the literature and recommendations for the future. *BMC Public Health* **18**, 336 (2018).
4. Reluga, T. Game theory of social distancing in response to an epidemic. *PLoS Comput. Biol.* **6**, e1000793. <https://doi.org/10.1371/journal.pcbi.1000793> (2010).
5. Chen, F., Jiang, M., Rabidoux, S. & Robinson, S. Public avoidance and epidemics: Insights from an economic model. *J. Theor. Biol.* **278**, 107–119 (2011).
6. Rhodes, C. & Anderson, R. Epidemic thresholds and vaccination in a lattice model of disease spread. *Theor. Popul. Biol.* **52**, 101–118 (1997).
7. Zhao, S., Wu, J. & Ben-Arieh, D. Modeling infection spread and behavioral change using spatial games. *Health Systems* **4**, 41–53. <https://doi.org/10.1057/hs.2014.22> (2015).
8. Xia, C. *et al.* A new coupled disease-awareness spreading model with mass media on multiplex networks. *Inf. Sci.* **471**, 185–200. <https://doi.org/10.1016/j.ins.2018.08.050> (2019).
9. Gómez, S., Arenas, A., Borge-Holthoefer, J., Meloni, S. & Moreno, Y. Discrete-time markov chain approach to contact-based disease spreading in complex networks. *Europhys. Lett.* **89**, 38009 (2010).
10. Kan, J.-Q. & Zhang, H.-F. Effects of awareness diffusion and self-initiated awareness behavior on epidemic spreading—An approach based on multiplex networks. *Commun. Nonlinear Sci. Numer. Simul.* **44**, 193–203 (2017).
11. Hota, A. R. & Sundaram, S. Game-theoretic vaccination against networked SIS epidemics and impacts of human decision-making. *IEEE Trans. Control Netw. Syst.* **6**, 1461–1472 (2019).
12. Zhang, H.-F., Wu, Z.-X., Tang, M. & Lai, Y.-C. Effects of behavioral response and vaccination policy on epidemic spreading—an approach based on evolutionary-game dynamics. *Sci. Rep.* **4**, 5666 (2014).
13. Schimit, P. & Monteiro, L. A vaccination game based on public health actions and personal decisions. *Ecol. Model.* **222**, 1651–1655 (2011).
14. Trajanovski, S., Hayel, Y., Altman, E., Wang, H. & Van Mieghem, P. Decentralized protection strategies against SIS epidemics in networks. *IEEE Trans. Control Netw. Syst.* **2**, 406–419 (2015).
15. Liu, X.-T., Wu, Z.-X. & Zhang, L. Impact of committed individuals on vaccination behavior. *Phys. Rev. E* **86**, 051132 (2012).
16. Kabir, K. A. & Tanimoto, J. Dynamical behaviors for vaccination can suppress infectious disease—A game theoretical approach. *Chaos Solitons Fractals* **123**, 229–239 (2019).
17. Kuga, K., Tanimoto, J. & Jusup, M. To vaccinate or not to vaccinate: A comprehensive study of vaccination-subsidizing policies with multi-agent simulations and mean-field modeling. *J. Theor. Biol.* **469**, 107–126 (2019).
18. Fu, F., Rosenbloom, D. I., Wang, L. & Nowak, M. A. Imitation dynamics of vaccination behaviour on social networks. *Proc. R. Soc. B Biol. Sci.* **278**, 42–49 (2011).
19. Hayashi, M. A. & Eisenberg, M. C. Effects of adaptive protective behavior on the dynamics of sexually transmitted infections. *J. Theor. Biol.* **388**, 119–130 (2016).
20. Bhattacharyya, S. & Bauch, C. T. Wait and see vaccinating behaviour during a pandemic: A game theoretic analysis. *Vaccine* **29**, 5519–5525 (2011).
21. Bauch, C. T. & Bhattacharyya, S. Evolutionary game theory and social learning can determine how vaccine scares unfold. *PLoS Comput. Biol.* **8**, e1002452 (2012).
22. Bauch, C. T. Imitation dynamics predict vaccinating behaviour. *Proc. R. Soc. B Biol. Sci.* **272**, 1669–1675 (2005).
23. Li, J., Lindberg, D. V., Smith, R. A. & Reluga, T. C. Provisioning of public health can be designed to anticipate public policy responses. *Bull. Math. Biol.* **79**, 163–190 (2017).
24. Wang, Y., Cao, J., Jin, Z., Zhang, H. & Sun, G.-Q. Impact of media coverage on epidemic spreading in complex networks. *Physica A* **392**, 5824–5835 (2013).
25. Wang, M., Pan, Q. & He, M. The effect of individual attitude on cooperation in social dilemma. *Physica A Stat. Mech. Appl.* **555**, 124424 (2020).
26. Jnawali, K., Morsky, B., Poore, K. & Bauch, C. T. Emergence and spread of drug resistant influenza: A two-population game theoretical model. *Infect. Dis. Model.* **1**, 40–51 (2016).
27. Wu, B., Fu, F. & Wang, L. Imperfect vaccine aggravates the long-standing dilemma of voluntary vaccination. *PLoS One* **6**, e20577 (2011).
28. Cai, C.-R., Wu, Z.-X. & Guan, J.-Y. Effect of vaccination strategies on the dynamic behavior of epidemic spreading and vaccine coverage. *Chaos Solitons Fractals* **62**, 36–43 (2014).
29. Blouin, C., Drager, N. & Smith, R. *International Trade in Health Services and the GATS: Current Issues and debates* (The World Bank, Washington, 2006).
30. Richardson, E. T. *et al.* The Ebola suspects dilemma. *Lancet Glob. Health* **5**, e254–e256 (2017).
31. Kaushik, P. Covid-19 and the Prisoner's Dilemma. *Asia Times*. <https://asiatimes.com/2020/03/covid-19-and-the-prisoners-dilemma> (2020). Accessed 09 Apr 2020.
32. Fukuda, E. & Tanimoto, J. Impact of stubborn individuals on a spread of infectious disease under voluntary vaccination policy. In *Proceedings of the 18th Asia Pacific Symposium on Intelligent and Evolutionary Systems. Proceedings in Adaptation, Learning and Optimization*, Vol. 1 (2015).
33. Stutt, R. O. J. H., Retkute, R., Bradley, M., Gilligan, C. A. & Colvin, J. A modelling framework to assess the likely effectiveness of facemasks in combination with lock-down in managing the covid-19 pandemic. *Proc. R. Soc. A* **476**, 20200376. <https://doi.org/10.1098/rspa.2020.0376> (2020).
34. Tanimoto, J. A simple scaling in the effectiveness of supporting mutual cooperation in donor-recipient games by various reciprocity mechanisms. *BioSystems* **96**, 29–34 (2009).
35. Ohtsuki, H. & Nowak, M. A. The replicator equation on graphs. *J. Theor. Biol.* **243**, 86–97 (2006).
36. Tanimoto, J. *Fundamentals of Evolutionary Game Theory and Its Applications. Evolutionary Economics and Social Complexity Science* Vol. 6 (Springer, Berlin, 2015).

37. Ohtsuki, H. & Nowak, M. A. Evolutionary games on cycles. *Proc. R. Soc. B* **273**, 2249–2256 (2006).
38. Taylor, M. A. & Nowak, C. Transforming the dilemma. *Evolution* **61**, 2281–2292 (2007).
39. Brams, S. J. *Theory of Moves* (Cambridge University Press, Cambridge, 1993).
40. Chen, X. & Fu, F. Imperfect vaccine and hysteresis. *J. R. Soc. B* **286**, 20182406. <https://doi.org/10.1098/rspb.2018.2406> (2019).
41. Chen, X. & Fu, F. Social learning of prescribing behavior can promote population optimum of antibiotic use. *Front. Phys.* **6**, 139. <https://doi.org/10.3389/fphy.2018.00139> (2018).
42. Bednar, J. & Page, S. Can game(s) theory explain culture? The emergence of cultural behavior within multiple games. *Ration. Soc.* **19**, 65–97 (2007).
43. Saltelli, A. *et al.* Five ways to ensure that models serve society: A manifesto. *Nature* **582**, 482–484 (2020).
44. Nowak, M. A. *Evolutionary Dynamics—Exploring the Equations of Life* (The Belknap Press of Harvard University Press, Cambridge, 2006).
45. Axelrod, R. & Hamilton, W. D. The evolution of cooperation. *Science* **211**, 1390–1396. <https://doi.org/10.1126/science.7466396> (1981).
46. Axelrod, R. Launching “The evolution of cooperation”. *J. Theoret. Biol.* **299**, 21–24. <https://doi.org/10.1016/j.jtbi.2011.04.015> (2012).
47. Nee, S. Does Hamiltons rule describe the evolution of reciprocal altruism?. *J. Theoret. Biol.* **141**, 81–91. [https://doi.org/10.1016/S0022-5193\(89\)80010-4](https://doi.org/10.1016/S0022-5193(89)80010-4) (1989).
48. Kreps, D. M., Milgrom, P., Roberts, J. & Robert, W. Rational cooperation in the finitely repeated prisoners’ dilemma. *J. Econ. Theory* **27**, 245–252 (1982).
49. Nowak, M. A. Evolutionary dynamics of cooperation. In *International Congress of Mathematicians*, Vol. III, 1523–1540 (European Mathematical Society, Zürich, 2006).
50. Rand, D. G., Dreber, A., Ellingsen, T., Fudenberg, D. & Nowak, M. A. Positive interactions promote public cooperation. *Science* **325**, 1272–1275. <https://doi.org/10.1126/science.1177418> (2009).
51. Nowak, M. A. Evolving cooperation. *J. Theoret. Biol.* **299**, 1–8. <https://doi.org/10.1016/j.jtbi.2012.01.014> (2012).
52. Bravetti, A. & Padilla, P. An optimal strategy to solve the prisoner’s dilemma. *Nat. Sci. Rep.* **8**, 1–6 (2018).
53. Poletti, P., Caprile, B., Ajelli, M., Pugliese, A. & Merler, S. Spontaneous behavioural changes in response to epidemics. *J. Theor. Biol.* **260**, 31–40 (2009).
54. Lin, Q. *et al.* A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action. *Int. J. Infect. Dis.* **93**, 211–216 (2020).
55. Romer, D. *et al.* Mass media as an hiv-prevention strategy: Using culturally sensitive messages to reduce HIV-associated sexual behavior of at-risk African American youth. *Am. J. Public Health* **12**, 2150–2159 (2009).
56. 20 years after Grim Reaper ad, AIDS fight continues. *ABC News Australia* (April 4, 2007).
57. Building on success 1—A review of gay and other homosexually active men’s HIV/AIDS education in Australia. Technical Report, Commonwealth of Australia, Commonwealth Department of Health and Family Services (1998).
58. Liu, T. *et al.* Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan—Implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2. *medRxiv* <https://doi.org/10.1101/2020.06.13.20130252> (2020).
59. Long, Q.-X. *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Natu. Med.* <https://doi.org/10.1038/s41591-020-0965-6> (2020).
60. Pollán, M. *et al.* Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. *The Lancet* [https://doi.org/10.1016/S0140-6736\(20\)31483-5](https://doi.org/10.1016/S0140-6736(20)31483-5) (2020).
61. Barthold, A. & Smith, S. W. Duration of challenge immunity to coronavirus JHM in mice. *Arch. Virol.* **107**, 171–177. <https://doi.org/10.1007/BF01317914> (1989).
62. Barrett, L. R., Alan, D. T. & Stanberry, J. *Vaccines for Biodefense and Emerging and Neglected Diseases* (Academic Press, Cambridge, 2009).

Acknowledgements

We are grateful to Philip Gerlee and Alessandro Bravetti for insightful discussions and suggesting relevant references. We thank Johan Runeson for the idea to use game theory to model human behaviour in the corona pandemic. Both authors are supported by Swedish Research Council Grant GAAME 2018-03873. The anonymous reviewers provided us with insightful comments and critiques which significantly improved the quality of this manuscript, for which we are deeply grateful. Open access funding provided by Chalmers University of Technology.

Author contributions

C.K. and J.R. contributed to all aspects of this work.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-020-69546-2>.

Correspondence and requests for materials should be addressed to J.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020